An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine

Vaccine

Volumn 31, Issue 18, 2013, Pages 2302-2309

  Alejo, Diana M ^a   Moraes, Mauro P ^a,c,d   Liao, Xiaofen ^a   Dias, Camila C ^b   Tulman, Edan R ^a   Segundo, Fayna Diaz San ^c   Rood, Debra ^a   Grubman, Marvin J ^c   Silbart, Lawrence K ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^d Ceva Biomune   (United States)

Author keywords

Adenovirus; Adjuvants; E. coli enterotoxin; FMDV; Mice; Mucosal immunity

Indexed keywords

ADENOVIRUS 5 VECTOR; ADENOVIRUS VECTOR; FOOT AND MOUTH DISEASE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; LETHAL DOSE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTYPE; SURVIVAL; VACCINATION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL TOXINS; CELL LINE; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENETIC VECTORS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED C57BL; SWINE; VACCINES, SUBUNIT; VIRAL VACCINES; VIREMIA;

EID: 84875879881     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.060     Document Type: Article

References (50)

1. Bachrach H.L. Foot-and-mouth disease: world-wide impact and control measures. Viruses and environment 1978, Academic Press, New York. E. Kurstak, K. Maramorosch (Eds.).
2. Alexandersen S., Zhang Z., Donaldson A.I., Garland A.J. The pathogenesis and diagnosis of foot-and-mouth disease. J Comp Pathol 2003 Jul, 129(1):1-36.
3. Arzt J., Pacheco J.M., Rodriguez L.L. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation. Identification of the nasopharynx as the primary site of infection. Vet Pathol 2010 Nov, 47(6):1048-1063.
4. Alexandersen S., Brotherhood I., Donaldson A.I. Natural aerosol transmission of foot-and-mouth disease virus to pigs: minimal infectious dose for strain O1 Lausanne. Epidemiol Infect 2002 Apr, 128(2):301-312.
5. Alexandersen S., Donaldson A.I. Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs. Epidemiol Infect 2002 Apr, 128(2):313-323.
6. Saraiva V. Vaccines and foot-and-mouth disease eradication in South America. Dev Biol (Basel) 2003, 114:67-77.
7. Barnett P.V., Pullen L., Williams L., Doel T.R. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine 1996 Sep, 14(13):1187-1198.
8. Lubroth J., Lopez A., Ramalho A.K., Meyer R.F., Brown F., Darsie G.C. Cattle response to foot-and-mouth disease virus nonstructural proteins as antigens within vaccines produced using different concentrations. Vet Q 1998, 20(Suppl. 2):S13-S17.
9. Defra FMD in Surrey, UK, 2007. Epidemiology report on the probable release of FMD virus at the Pirbright site and the transmission of infection to the first infected cattle herd, from investigations up to 29 August 2007 (Day 26). In: Department for Environment Food and Rural Affairs U; 2007.
10. Brown F. The importance of antigenic variation in vaccine design. Arch Virol (Suppl) 1963, 9:1-8.
11. Eble P.L., Bouma A., Weerdmeester K., Stegeman J.A., Dekker A. Serological and mucosal immune responses after vaccination and infection with FMDV in pigs. Vaccine 2007 Jan 22, 25(6):1043-1054.
12. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002 Feb 22, 20(11-12):1631-1639.
13. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008, 3(10):e3548.
14. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003, 77(Sep (18)):10078-10087.
15. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003, 77(Oct (20)):10780-10789.
16. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19(Mar (17-19)):2534-2541.
17. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 1999, 20(Nov (11)):493-500.
18. Giuliani M.M., Del Giudice G., Giannelli V., Dougan G., Douce G., Rappuoli R., et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998, 187(Apr (7)):1123-1132.
19. Pizza M., Domenighini M., Hol W., Giannelli V., Fontana M.R., Giuliani M.M., et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol Microbiol 1994, 14(Oct (1)):51-60.
20. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995, 63(May (5)):1617-1623.
21. Neidleman J.A., Vajdy M., Ugozzoli M., Ott G., O'Hagan D. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 2000, 101(Sep (1)):154-160.
22. Simmons C.P., Hussell T., Sparer T., Walzl G., Openshaw P., Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol 2001, 166(Jan (2)):1106-1113.
23. Baudner B.C., Morandi M., Giuliani M.M., Verhoef J.C., Junginger H.E., Costantino P., et al. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J Infect Dis 2004, 189(Mar (5)):828-832.
24. Bonenfant C., Dimier-Poisson I., Velge-Roussel F., Buzoni-Gatel D., Del Giudice G., Rappuoli R., et al. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001, 69(Mar (3)):1605-1612.
25. Barrette R.W., Szczepanek S.M., Rood D., Challa S., Avery N., Vajdy M., et al. Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine. Clin Vaccine Immunol 2011, 18(Nov (11)):1996-1998.
26. Yamamoto M., Kiyono H., Kweon M.N., Yamamoto S., Fujihashi K., Kurazono H., et al. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses. J Infect Dis 2000, 182(Jul (1)):180-190.
27. Takahashi I., Marinaro M., Kiyono H., Jackson R.J., Nakagawa I., Fujihashi K., et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996, 173(Mar (3)):627-635.
28. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(Feb (9)):896-903.
29. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165(Nov (9)):4778-4782.
30. Zurbriggen R., Metcalfe I.C., Gluck R., Viret J.F., Moser C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines 2003, 2(Apr (2)):295-304.
31. Moraes M.P., Mayr G.A. Grubman MJ. pAd5-Blue: direct ligation system for engineering recombinant adenovirus constructs. Biotechniques 2001, 31(Nov (5)):1050. 2, 4-6.
32. Graham F.L., Prevec L. Manipulation of adenovirus vectors. Methods Mol Biol 1991, 7:109-128.
33. Savage K.E., Baur P.S. Effect of tunicamycin, an inhibitor of protein glycosylation, on division of tumour cells in vitro. J Cell Sci 1983, 64(Nov):295-306.
34. Moraes MP, Diaz-San Segundo F, Dias CC, Pena L, Grubman MJ. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine 2011 Nov 28;29(51):9431-40.
35. Salguero FJ, Sanchez-Martin MA, Diaz-San Segundo F, de Avila A, Sevilla N. Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 2005 Feb 5;332(1):384-96.
36. Amuguni J.H., Lee S., Kerstein K.O., Brown D.W., Belitsky B.R., Herrmann J.E., et al. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine 2011, 29(Jun (29-30)):4778-4784.
37. Morris J.B., Stanek J., Gianutsos G. Sensory nerve-mediated immediate nasal responses to inspired acrolein. J Appl Physiol 1999, 87(Nov (5)):1877-1886.
38. Crespo Leon F., Gutierrez Diez F., Rodriguez Ferri F., Leon Vizcaino L., Cuello Gijon F., Gimeno E.J., et al. The translation into Spanish of the OIE Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds and bees): problems, solutions and conclusions. Rev Sci Tech 2005, 24(Dec (3)):1095-1104.
39. de Avila Botton S., Brum M.C., Bautista E., Koster M., Weiblen R., Golde W.T., et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006, 24(Apr (17)):3446-3456.
40. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12(Aug (8)):592-605.
41. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(Feb (2)):148-158.
42. Santosuosso M., McCormick S., Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18(2):283-291.
43. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988, 6(Jun (3)):269-277.
44. Simmons C.P., Ghaem-Magami M., Petrovska L., Lopes L., Chain B.M., Williams N.A., et al. Immunomodulation using bacterial enterotoxins. Scand J Immunol 2001, 53(Mar (3)):218-226.
45. Du L., Zhao G., Lin Y., Sui H., Chan C., Ma S., et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008, 180(Jan (2)):948-956.
46. Guzman E., Taylor G., Charleston B., Skinner M.A., Ellis S.A. An MHC-restricted CD8+ T-cell response is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV. J Gen Virol 2008, 89(Mar (Pt 3)):667-675.
47. McCullough K.C., De Simone F., Brocchi E., Capucci L., Crowther J.R., Kihm U. Protective immune response against foot-and-mouth disease. J Virol 1992, 66(Apr (4)):1835-1840.
48. Simmons C.P., Mastroeni P., Fowler R., Ghaem-maghami M., Lycke N., Pizza M., et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 1999, 163(Dec (12)):6502-6510.
49. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4(Sep (9)):699-710.
50. Patel A., Zhang Y., Croyle M., Tran K., Gray M., Strong J., et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 2007, 196(Nov (Suppl 2)):S413-S420.